Manifestation of epidemic process, clinical and epidemiological characteristics of adult patients in the early period of the COVID-19 epidemic in Russia

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: The COVID-19 pandemic became a challenge and caused significant social and economic damage to most countries. For the most objective assessment of the epidemiological and clinical features of COVID-19 during different periods of the epidemic, studies based on a large volume of data on patients identified throughout the Russian Federation are necessary.

AIM: To analyze the epidemic process and clinical and epidemiological features of adult patients with COVID-19 identified during the first and second periods of the rise and decline in the incidence of COVID-19 in Russia.

MATERIALS AND METHODS: This study included patients aged ≥18 years with a confirmed diagnosis of COVID-19 and identified in the periods from March 2, 2020, to June 30, 2020 (n=286,205) and from November 1, 2020, to January 31, 2021 (n=1 655 022), in Russia.

RESULTS: At the early stage of the COVID-19 epidemic in Russia, two periods of the rise and fall in incidence were noted: March–August 2020 and September 2020–May 2021, using the Wald–Wolfowitz test. The median age of the patients with COVID-19 in the first and second periods were 50.0 [37–62] and 52.0 [39–64] years, respectively, and women accounted for 55.5 and 60.1% of the patients, respectively. The distributions of patients according to disease severity in the first and second periods were as follows: mild, 63.0 and 74.4%; moderate, 29.0 and 20.1%; severe, 4.9 and 3.5%; extremely severe, 3.1 and 2.1%, respectively. In the first and second periods, cases were dominated by patients aged 50–59 years (20.5%) and 60–69 years (20.5%), respectively. In both periods, the median duration from the onset of symptoms to diagnosis was 4 days, the median disease durations were 16.0 [12–21] and 13 [10–17], and the median duration of hospitalization were 15.0 [12–20] and 13.0 [10–18]. The hospitalization rates were 48.4 and 25.6% in the first and second periods; transfer rates to the ICU, 7.8 and 10.3%; and invasive mechanical ventilation rates, 5.6 and 7.7%, respectively. In both periods, the median age at death was 73 [66–82] years, with a higher proportion of men aged 30–39, 40–49, 50–59, and 60–69 years. The presence of one or more chronic diseases, as well as male sex, increased the likelihood of death (odds ratio = 10.2 and 1.3 in the first period; odds ratio = 16.0 and 1.6 in the second period).

CONCLUSIONS: In the early period of the COVID-19 epidemic in Russia, related to the spread of the wild strain of SARS-CoV-2 and genetically closely related variants, the manifestations of the epidemic process and clinical and epidemiological characteristics of patients varied. In the second period with higher incidence and mortality rates than the first period, the frequency of severe and extremely severe COVID-19 and the frequency and duration of hospitalizations decreased; however, the frequency of transfers into the intensive care unit and artificial lung ventilation slightly increased.

About the authors

Anastasia A. Fomicheva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: anastasia.fomichova@yandex.ru
ORCID iD: 0000-0002-0625-0284
SPIN-code: 5281-1670
Russian Federation, Moscow

Nikolay N. Pimenov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: n.pimenov@mail.ru
ORCID iD: 0000-0002-6138-4330
SPIN-code: 2314-2076

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Svetlana V. Komarova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: svet056@yandex.ru
ORCID iD: 0000-0002-7681-5455
SPIN-code: 2810-3381
Russian Federation, Moscow

Aleksandr V. Urtikov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: urtikovav@mail.ru
ORCID iD: 0000-0001-7319-0712
SPIN-code: 7260-6505
Russian Federation, Moscow

Artur R. Sakhautdinov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: sahautdinov91@gmail.com
ORCID iD: 0009-0006-3709-3900
SPIN-code: 4179-8094
Russian Federation, Moscow

Daria A. Strelkova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: dashastrelkova@gmail.com
ORCID iD: 0000-0002-2124-0623
SPIN-code: 9549-8053
Russian Federation, Moscow

Galina V. Nekludova

I.M. Sechenov First Moscow State Medical University (Sechenov University); Pulmonology Scientific Research Institute

Email: nekludova_gala@mail.ru
ORCID iD: 0000-0002-9509-0867
SPIN-code: 8956-9125

MD, Dr. Sci. (Medicine), Associate Professor

Russian Federation, Moscow; Moscow

Svetlana A. Rachina

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: rachina_s_a@staff.sechenov.ru
ORCID iD: 0000-0002-3329-7846
SPIN-code: 1075-7329

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Sergey N. Avdeev

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: serg_avdeev@list.ru
ORCID iD: 0000-0002-5999-2150
SPIN-code: 1645-5524

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Vladimir P. Chulanov

I.M. Sechenov First Moscow State Medical University (Sechenov University); National Medical Research Center for Phthisiopulmonology and Infectious Diseases; Sirius University of Science and Technology

Email: vladimir@chulanov.ru
ORCID iD: 0000-0001-6303-9293
SPIN-code: 2336-4545

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow; Moscow; Sochi

References

  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5 Erratum in: Lancet. 2020;395(10223):496. doi: 10.1016/S0140-6736(20)30252-X
  2. Archived. WHO Timeline — COVID-19. WHO [Internet]. Available from: https://www.who.int/news/item/27-04-2020-who-timeline---covid-19
  3. Listings of WHO’s response to COVID-19. WHO [Internet]. Available from: https://www.who.int/news-room/detail/29-06-2020-covidtimeline
  4. Listings of WHO’s response to COVID-19 [Internet]. Available from: https://www.who.int/ru/news-room/detail/29-06-2020-covidtimeline (In Russ).
  5. Naming the coronavirus disease (COVID-19) and the virus that causes it. WHO [Internet]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
  6. Karpova LS, Stolyarov KA, Popovtseva NM, Stolyarova TP, Danilenko DM. Comparison of the First Three Waves of the COVID-19 Pandemic in Russia in 2020–21. Epidemiology and Vaccinal Prevention. 2022;21(2):4–16. (In Russ). doi: 10.31631/2073-3046-2022-21-2-4-16
  7. Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182(4):812–827.e19. doi: 10.1016/j.cell.2020.06.043
  8. Historical working definitions and primary actions for SARS-CoV-2 variants. WHO [Internet]. Available from: https://www.who.int/publications/m/item/historical-working-definitions-and-primary-actions-for-sars-cov-2-variants
  9. Ombajo LA, Mutono N, Sudi P, et al. Epidemiological and clinical characteristics of patients hospitalised with COVID-19 in Kenya: a multicentre cohort study. BMJ Open. 2022;12(5):e049949. doi: 10.1136/bmjopen-2021-049949
  10. Nikpouraghdam M, Jalali Farahani A, Alishiri G, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol. 2020;127:104378. doi: 10.1016/j.jcv.2020.104378
  11. Peckham H, de Gruijter NM, Raine C, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317. doi: 10.1038/s41467-020-19741-6
  12. Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. 2020;20(1):1742. doi: 10.1186/s12889-020-09826-8
  13. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–e25. doi: 10.1016/j.jinf.2020.04.021
  14. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574–1581. doi: 10.1001/jama.2020.5394 Erratum in: JAMA. 2021;325(20):2120. doi: 10.1001/jama.2021.5060
  15. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi: 10.1016/j.ijid.2020.03.017
  16. Xu JW, Liu JQ, Ke L, et al. Effective actions against the second wave of COVID-19: the front-line experience from China. Eur Rev Med Pharmacol Sci. 2020;24(23):11995–11997. doi: 10.26355/eurrev_202012_23986
  17. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. China CDC Weekly. 2020;2(8):113–122. doi: 10.46234/ccdcw2020.032
  18. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi: 10.1183/13993003.00547-2020
  19. COVID-19 integrated surveillance data in Italy. EpiCentro [Internet]. Available from: https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-dashboard
  20. Covid-19 — Folkhälsomyndigheten [Internet]. Available from: https://experience.arcgis.com/experience/09f821667ce64bf7be6f9f87457ed9aa (In Swedish).
  21. COVID-19 WEEKLY EPIDEMIOLOGY BRIEF. National Institute for Communicable Diseases [Internet]. Available from: https://www.nicd.ac.za/wp-content/uploads/2020/07/NICD-Weekly-Epidemiological-Brief_-Week-ending-11-July-2020.-final-pdf.pdf
  22. COVID-19: point épidémiologique du 17 juillet 2020. Sante publique France [Internet]. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-17-juillet-2020 (In French).
  23. Akande OW, Elimian KO, Igumbor E, et al. Epidemiological comparison of the first and second waves of the COVID-19 pandemic in Nigeria, February 2020–April 2021. BMJ Glob Health. 2021;6(11):e007076. doi: 10.1136/bmjgh-2021-007076
  24. BOLETIM EPIDEMIOLÓGICO ESPECIAL Doença pelo Coronavírus COVID-19. Ministério da Saúde [Internet]. Available from: http://saude.gov.br/images/pdf/2020/July/15/Boletim-epidemiologico-COVID-22.pdf (In Portuguese).
  25. Aleksanyan Y, Weinman JP. Women, men and COVID-19. Soc Sci Med. 2022;294:114698. doi: 10.1016/j.socscimed.2022.114698
  26. Schlichthorst M, Sanci LA, Pirkis J, Spittal MJ, Hocking JS. Why do men go to the doctor? Socio-demographic and lifestyle factors associated with healthcare utilisation among a cohort of Australian men. BMC Public Health. 2016;16 Suppl. 3:1028. doi: 10.1186/s12889-016-3706-5
  27. Leong R, Lee TJ, Chen Z, Zhang C, Xu J. Global Temporal Patterns of Age Group and Sex Distributions of COVID-19. Infect Dis Rep. 2021;13(2):582–596. doi: 10.3390/idr13020054
  28. Yang C, Zhang S, Lu S, et al. All five COVID-19 outbreaks during epidemic period of 2020/2021 in China were instigated by asymptomatic or pre-symptomatic individuals. J Biosaf Biosecur. 2021;3(1):35–40. doi: 10.1016/j.jobb.2021.04.001
  29. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672–675. doi: 10.1038/s41591-020-0869-5
  30. Buttenschøn HN, Lynggaard V, Sandbøl SG, et al. Comparison of the clinical presentation across two waves of COVID-19: A retrospective cohort study. BMC Infect Dis. 2022;22(1):423. doi: 10.1186/s12879-022-07413-3
  31. Hoogenboom WS, Pham A, Anand H, et al. Clinical characteristics of the first and second COVID-19 waves in the Bronx, New York: A retrospective cohort study. Lancet Reg Health Am. 2021;3:100041. doi: 10.1016/j.lana.2021.100041
  32. Goel I, Sharma S, Kashiramka S. Effects of the COVID-19 pandemic in India: An analysis of policy and technological interventions. Health Policy Technol. 2021;10(1):151–164. doi: 10.1016/j.hlpt.2020.12.001
  33. Matsunaga N, Hayakawa K, Asai Y, et al. Clinical characteristics of the first three waves of hospitalised patients with COVID-19 in Japan prior to the widespread use of vaccination: a nationwide observational study. Lancet Reg Health West Pac. 2022;22:100421. doi: 10.1016/j.lanwpc.2022.100421
  34. Smits RAL, Trompet S, van der Linden CMJ, et al. Characteristics and outcomes of older patients hospitalised for COVID-19 in the first and second wave of the pandemic in The Netherlands: the COVID-OLD study. Age Ageing. 2022;51(3):afac048. doi: 10.1093/ageing/afac048
  35. Amin R, Sohrabi MR, Zali AR, Hannani K. Five consecutive epidemiological waves of COVID-19: a population-based cross-sectional study on characteristics, policies, and health outcome. BMC Infect Dis. 2022;22(1):906. doi: 10.1186/s12879-022-07909-y
  36. Bobik TV, Kostin NN, Skryabin GA, et al. COVID-19 in Russia: clinical and immunological features of the first-wave patients. Acta Naturae. 2021;13(1):102–115. (In Russ). doi: 10.32607/actanaturae.11374
  37. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Archives of Academic Emergency Medicine. 2020;8(1):e35.
  38. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458–464. doi: 10.15585/mmwr.mm6915e3
  39. Demography. Federal State Statistics Service [Internet]. Available from: https://rosstat.gov.ru/folder/12781 (In Russ).
  40. Shestakova MV, Vikulova OK, Isakov MА, Dedov II. Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the russian diabetes registry. Problems of Endocrinology. 2020;66(1):35–46. (In Russ). doi: 10.14341/probl12458
  41. Jacobsen H, Klein SL. Sex Differences in Immunity to Viral Infections. Frontiers in Immunology. 2021;12:720952. doi: 10.3389/fimmu.2021.720952
  42. Briko NI, Korshunov VA, Krasnova SV, et al. Clinical and epidemiological characteristics of hospitalized patients with COVID-19 during different pandemic periods in Moscow. Journal of microbiology, epidemiology and immunobiology 2022;99(3):287–299. (In Russ.) doi: 10.36233/0372-9311-272

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Dynamics of COVID-19 incidence and mortality in the early period of the epidemic of a new coronavirus infection in Russia (Wald–Wolfowitz test, р <0.05).

Download (766KB)
3. Fig. 2. Age and sex structure of patients with COVID-19 in the first and second waves of COVID-19 in Russia (chi-squared test, р <0.05).

Download (755KB)
4. Fig. 3. COVID-19 severity in various age groups in the first and second waves of COVID-19 in Russia (chi-squared test, р <0.05).

Download (935KB)
5. Fig. 4. COVID-19 severity in various age groups of hospitalized patients during the first and second waves of COVID-19 in Russia (chi-squared test, р <0.05).

Download (785KB)
6. Fig. 5. Age and sex structure of deceased patients with COVID-19 in the first and second waves of new coronavirus infection in Russia (chi-squared test, р <0.05).

Download (759KB)

Copyright (c) 2024 Eco-vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies